Perspectives on the Current State of the Biosimilar Regulatory Pathway in the United States
- 20 November 2017
- journal article
- editorial
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 103 (1) , 36-38
Abstract
The Biologics Price Competition and Innovation Act of 2009 (BPCI Act) created an abbreviated licensure pathway in the United States that allows for the development and approval of biologic products shown to be biosimilar to or interchangeable with a US Food and Drug Administration (FDA)‐licensed reference product (Table 1). Here we discuss implementation of the US biosimilar approval pathway and the role of various types of data, including clinical pharmacology data, in biosimilar development.Keywords
This publication has 4 references indexed in Scilit:
- Mechanisms of G-CSF-mediated hematopoietic stem and progenitor mobilizationLeukemia, 2010
- G-CSF: A key regulator of neutrophil production, but that's not all!Growth Factors, 2005
- Peripheral blood progenitor cells for HPC transplants involving unrelated donorsTransfusion, 2000
- Effect of escalating doses of recombinant human granulocyte colony—stimulating factor (filgrastim) on circulating neutrophils in healthy subjectsClinical Therapeutics, 1998